Glycomimetics Inc GLYC
We take great care to ensure that the data presented and summarized in this overview for GLYCOMIMETICS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding GLYC
View all-
Bvf Inc San Francisco, CA9.54MShares$150 Million0.09% of portfolio
-
Logos Global Management LP San Francisco, CA5.4MShares$84.8 Million0.22% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.09MShares$79.9 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3MShares$47.1 Million0.15% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.67MShares$41.9 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA1.37MShares$21.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY723KShares$11.4 Million0.0% of portfolio
-
Jefferies Financial Group Inc. New York, NY585KShares$9.18 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA572KShares$8.98 Million0.0% of portfolio
-
Ubs Group Ag466KShares$7.31 Million0.0% of portfolio
Latest Institutional Activity in GLYC
Top Purchases
Top Sells
About GLYC
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
Insider Transactions at GLYC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 13
2025
|
Bvf Partners L P > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
1,270,004
+47.97%
|
-
|
|
Aug 08
2024
|
Invus Public Equities, L.P. |
SELL
Open market or private sale
|
Direct |
260,873
-3.97%
|
$0
$0.19 P/Share
|
|
Aug 07
2024
|
Invus Public Equities, L.P. |
SELL
Open market or private sale
|
Direct |
61,488
-0.93%
|
$0
$0.18 P/Share
|
|
Aug 06
2024
|
Invus Public Equities, L.P. |
SELL
Open market or private sale
|
Direct |
55,732
-0.83%
|
$0
$0.18 P/Share
|
|
Aug 05
2024
|
Invus Public Equities, L.P. |
SELL
Open market or private sale
|
Direct |
164,523
-2.4%
|
$0
$0.19 P/Share
|
|
Aug 02
2024
|
Invus Public Equities, L.P. |
SELL
Open market or private sale
|
Direct |
286,200
-4.0%
|
$0
$0.2 P/Share
|
|
Aug 01
2024
|
Invus Public Equities, L.P. |
SELL
Open market or private sale
|
Direct |
63,564
-0.88%
|
$0
$0.22 P/Share
|
|
Jul 30
2024
|
Invus Public Equities, L.P. |
SELL
Open market or private sale
|
Direct |
756,835
-9.5%
|
$0
$0.22 P/Share
|
|
Jul 29
2024
|
Invus Public Equities, L.P. |
SELL
Open market or private sale
|
Direct |
363,949
-4.37%
|
$0
$0.24 P/Share
|
|
Jul 26
2024
|
Invus Public Equities, L.P. |
SELL
Open market or private sale
|
Direct |
258,335
-3.01%
|
$0
$0.24 P/Share
|
|
Jun 21
2024
|
Edwin Rock Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
115,000
+14.46%
|
$0
$0.27 P/Share
|
|
Jun 20
2024
|
Edwin Rock Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
190,000
+25.15%
|
$0
$0.25 P/Share
|
|
Jun 18
2024
|
Brian M. Hahn SVP Finance, CFO |
BUY
Open market or private purchase
|
Direct |
17,500
+19.85%
|
$0
$0.25 P/Share
|
|
Mar 29
2024
|
Mark Alan Goldberg |
BUY
Grant, award, or other acquisition
|
Direct |
4,584
+15.59%
|
$13,752
$3.0 P/Share
|
|
Mar 29
2024
|
Rachel K. King |
BUY
Grant, award, or other acquisition
|
Direct |
3,334
+0.64%
|
$10,002
$3.0 P/Share
|
|
Mar 29
2024
|
Daniel M Junius |
BUY
Grant, award, or other acquisition
|
Direct |
5,209
+5.02%
|
$15,627
$3.0 P/Share
|
|
Dec 29
2023
|
Mark Alan Goldberg |
BUY
Grant, award, or other acquisition
|
Direct |
5,827
+22.35%
|
$11,654
$2.36 P/Share
|
|
Dec 29
2023
|
Rachel K. King |
BUY
Grant, award, or other acquisition
|
Direct |
4,238
+0.82%
|
$8,476
$2.36 P/Share
|
|
Dec 29
2023
|
Patricia S Andrews |
BUY
Grant, award, or other acquisition
|
Direct |
5,191
+8.14%
|
$10,382
$2.36 P/Share
|
|
Sep 30
2023
|
Mark Alan Goldberg |
BUY
Grant, award, or other acquisition
|
Direct |
9,167
+38.87%
|
$9,167
$1.5 P/Share
|
Last 12 Months Summary
| Other acquisition or disposition | 1.27M shares |
|---|---|
| Open market or private purchase | 305K shares |
| Open market or private sale | 2.27M shares |
|---|